ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS)
August 23, 2011
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announced that new data, including six month outcomes, from its pivotal ocriplasmin Phase III clinical program were presented at the 2011 ASRS Annual Meeting in Boston, USA (20-24 August 2011).
Ocriplasmin is a novel pharmacological agent being investigated for the treatment of symptomatic vitreomacular adhesion (VMA) including macular holes. Symptomatic VMA is a condition when the vitreous gel adheres in an abnormally strong manner to the retina. VMA can lead to loss or distortion of visual acuity.
Click here for the full press release.
You might also enjoy...
- Ocriplasmin Approved by FDA to Treat Vitreomacular Adhesion
- ThromboGenics Launches JETREA® in United States for Non-Surgical Treatment of Vitreomacular Adhesion
- ThromboGenics Completes Patient Enrollment in Microplasmin Trial
- ThromboGenics Announces Testing of Medical Treatment for Vitreomacular Adhesions Underway
- Removing ILM Prevents Macular Pucker Recurrence
Jump down to form below to submit your own comments